2nd World Congress on Interventional Therapies for Type 2 Diabetes

Transcription

2nd World Congress on
Interventional Therapies for Type 2 Diabetes
M a rc h 2 8 - 3 0 , 2 0 1 1
H i l t o n N e w Yo r k
•
N e w Yo r k , N Y
•
USA
Congress Director
Francesco Rubino, MD
Congress Program
www.wcidt.org
Hosted By
Welcome to the 2nd World Congress on
Interventional therapies for Type 2 diabetes
Dear Colleagues and Friends,
Several gastrointestinal (GI) operations originally designed to treat morbid obesity also
cause dramatic improvement or even remission of type 2 diabetes. The mechanisms
by which surgery controls hyperglycemia remain elusive. Increasing evidence suggests
that weight-independent mechanisms may play a role in the surgical control of diabetes.
This knowledge challenges current paradigms of disease pathogenesis and points to the
gastrointestinal tract as a potential target for the development of less invasive interventional
therapies and novel pharmaceuticals.
Previously, the Diabetes Surgery Summit (Rome 2007) and the 1st World Congress on
Interventional Therapies for Type 2 Diabetes (New York 2008), have raised attention about
the role of gastrointestinal surgery for the treatment of diabetes: opportunities and
limitations of this emerging field are now the matter of a growing debate.
The debate continues with the 2nd World Congress on Interventional Therapies for Type 2
Diabetes. A multidisciplinary group of clinicians, scientists and policy makers will address
barriers that still prevent access to surgical treatment of diabetes in eligible patients and
develop an agenda of research priorities to improve patients selection and elucidate
mechanisms of diabetes control.
A stellar Faculty of leading international scientists will also discuss how the lessons learned
from study of gastrointestinal interventions may improve understanding of diabetes and
provide a lead for future treatments of curative intent.
On behalf of the organizing committee and myself, I welcome you to this exciting,
multidisciplinary event.
Congress Director
1
EDUCATIONAL PARTNER
American Diabetes Association
ENDORSING SOCIETIES
The 2nd World Congress on Interventional Therapies for Type 2 Diabetes is endorsed by the following organizations.
™
100 SW 75th Street Suite 201
Gainesville, FL 32607
American Association of
Clinical Endocrinologists
Asociacion
De Cirugia Bariatrica
Y Metabolica De
Guatemala
American Association of
Endocrine Surgeons
American Gastroenterological
Association
American Society for Metabolic
and Bariatric Surgery
Asia Pacific, Metabolic &
Bariatric Surgery Society
Asociation Latinoamericana
De Circurjanos Endoscpistas
Association for the
Study of Obesity
Emirates Obesity
Surgery
Interest Group
Belgian Endocrine Society
European Association
for Gastroenterology
and Endoscopy
International Atherosclerosis
Society
2
Diabetes UK
Canadian Diabetes
Association
IFSO Sweden
European Association for
the Study of Diabetes
Indian Association of Gastrointestinal
Endo-Surgeons
European Association for
Endoscopic Surgery
Endocrine Society
•
March 28-30, 2011
•
International Federation for the Surgery
of Obesity and Metabolic Disorders
New York, NY, USA
•
www.wcidt.org
Japan Society for the Study
of Obesity
Italian Society of
Endocrinology
The Obesity Society
Obesity & Metabolic Surgery
Society of India
Qatar Diabetes
Association – Qatar Foundation
Sociedade Brasileira
de Diabetes (SBD)
The New York
Academy of Sciencs
National Obesity Forum
Obesity Surgery Society of
Australia & New Zealand
The Philippine Society for
Metabolic and Bariatric Surgery
Research Society
for the Study of
Diabetes in India
Sociedad Argentina
de Diabetes
Sociedade Brasileira de
Endocronologia e Metabologia
Sociedade Brasileira de Cirurgia
Bariatrica e Metabolica
Sociedad de Cirujanos
de Chile
Sociedad Espanola
de Diabetes
Società
Italiana
di Diabetologia
Società Italiana dell'Obesità
Society for
Endocrinology
Società Italiana di Chirurgia dell’Obesità
e delle malattie metaboliche
Society of American Gastrointestinal
and Endoscopic Surgeons
Società Italiana per la
Prevezione Cardiovascolare
The Society for Surgery
of the Alimentary Tract
Swiss Society for the Study of Morbid
Obesity and Metabolic Disorders
This program is supported in name only by the American Heart Association’s Councils on Basic Cardiovascular Sciences,
Clinical Cardiology, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, Kidney in CV Disease,
and High Blood Pressure Research. http://www.heart.org/HEARTORG/
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
3
The International Diabetes Federation (IDF)
Position Statement on
Interventional Treatments of Type 2 Diabetes
During the World Congress, the IDF will officially announce its Position Statement on
Metabolic/Bariatric Surgery and GI Interventions for the Treatment of Diabetes
Monday, March 28, 2011
11:10 am - 12:30 pm • Grand Ballroom, Hilton New York
The IDF consensus developing meeting was held at the IDF head office in Brussels, Belgium (5-6 December, 2010).
This meeting was convened by:
Professor George Alberti
Professor Paul Zimmet
Imperial College, London and Newcastle University, UK
Baker IDI Heart & Diabetes Institute, Melbourne, Australia
Professor John B. Dixon
Professor Francesco Rubino
Baker IDI Heart & Diabetes Institute, Melbourne, Australia
Weill Cornell Medical College, New York, NY, USA
Other attendees at the meeting were:
Professor Stephanie Amiel
Professor Pierre Lefebvre
King's College London, UK
IDF and University of Liege, Belgium
Professor Louise A. Baur
Dr. Carel Le Roux
University of Sydney, Australia
Imperial College London, UK
Professor Nam H. Cho
Professor Jean-Claude Mbanya
Ajou University School of Medicine, Korea
International Diabetes Federation, Cameroon
Dr. Bruno Geloneze
Professor Gertrude Mingrone
University of Campinas (UNICAMP), Brazil
Catholic University of Rome, Italy
Professor Jan Willem Greve
Professor Philip R. Schauer
Atrium Medical Center, Netherlands
Cleveland Clinic Lerner College of Medicine, USA
Professor Linong Ji
Professor Luc Van Gaal
Peking University People's Hospital, China
Antwerp University Hospital, Belgium
Dr. Muffazal Lakdawala
Dr. David Whiting
Saifee Hospital, India
International Diabetes Federation, Belgium
Professor Wei-Jei Lee
Professor Bruce M. Wolfe
Ming-Sheng General Hospital, National Taiwan
University, Taiwan
Oregon Health and Science University (OHSU), USA
All panel members made a substantial contribution to the meeting and subsequent formulation of the position statement.
The consensus meeting was supported with an unrestricted educational grant by:
Allergan Inc, Irvine, CA, USA
Ethicon, Ethicon Endo-Surgery, Inc, Cincinnati, Ohio, USA
MetaCure Inc, Mount Laurel, NJ, USA
These companies played no role in the discussion or preparation of the IDF position statement.
4
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
Contents
Welcome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Endorsing Societies . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2-3
International Diabetes Federation Statement. . . . . . . . . . . . . . .
4
General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6-7
Congress Advisory Committee . . . . . . . . . . . . . . . . . . . . . . . 9
Congress Program Committee . . . . . . . . . . . . . . . . . . . . . 11-13
Distinguished Faculty . . . . . . . . . . . . . . . . . . . . . . . . . . 14-21
Guest Experts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Program-At-A-Glance . . . . . . . . . . . . . . . . . . . . . . . . . 23-24
PROGRAM
Monday, March 28. . . . . . . . . . . . . . . . . . . . . . . . . . 26-27
Tuesday, March 29. . . . . . . . . . . . . . . . . . . . . . . . . . 28-32
Breakout Sessions/Workshops . . . . . . . . . . . . . . . . . . . 30-32
Wednesday, March 30. . . . . . . . . . . . . . . . . . . . . . . . 33-34
Faculty Index. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Exhibitor Directory . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37-38
Exhibit Floor Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Poster Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
Diabetes: A Global Epidemic . . . . . . . . . . . . . . . . . . . . . . . 41
Gastrointestinal Procedures . . . . . . . . . . . . . . . . . . . . . . 43-47
Disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48-49
Congress Sponsors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
GENERAL INFORMATION
The World Congress will take place March 28-30, 2011
at the Hilton New York, 1335 Avenue of the Americas, New York, NY 10013
Telephone: (+1) 212-586-7000 • Guest Fax: (+1) 212-315-1374
EDUCATIONAL DISCLAIMER
The primary purpose of this congress is education. Information
presented, as well as publications, technologies, and/or services
discussed, are intended to inform you about the knowledge,
techniques, and experiences of the faculty who are willing to
share such information with colleagues. A diversity of
professional opinions exists on the topics of the Congress, and
the views of the conference’s faculty are solely for educational
purposes. Faculty’s views neither represent those of the 2nd
World Congress on Interventional Therapies for Type 2 Diabetes
nor constitute endorsement by the endorsing societies listed in
this syllabus. The Congress declaims any and all liability or
damages to any individual attending this conference and for
all claims, which may result from the use of information,
publications, technologies, products and/or services of the
meeting. Faculty disclosure statements have been provided
by speakers and are included at the end of this syllabus.
SPEAKER READY ROOM
All Congress speakers are required to check in at the Speaker
Ready Room no later than two hours in advance of your
presentation. The Speaker Ready Room is located in the
Gibson Suite on the hotel’s second floor.
Speaker Ready Room Hours:
Sunday, March 27, 2011
Tuesday, March 29, 2011
Wednesday, March 30, 2011
REGISTRATION
Registration Hours:
Sunday, March 27, 2011
ACCREDITATION
Due to the structure and multidisciplinary nature of the Congress,
continuing medical education and nursing credits are not
available through the Congress this year.
Attend all Scientific Sessions
Attend the Exhibits, and the Poster Sessions
• Receive Final Program and Abstracts
• Breakfast and Coffee Breaks March 28-30 and Boxed
Lunches on March 28-29
•
Second Floor
• Promenade - World Congress Registration
• Clinton Suite - Press Office
• Gibson Suite - Speaker Ready Room
• Rhinelander Gallery - Exhibits, Poster Sessions,
Continental Breakfasts and Lunches
• Sutton Center - Breakout Sessions
• Sutton North/Beekman - Breakout Sessions
• Sutton South/Regent - Breakout Sessions
•
BADGES
The official badge must be worn for admission to all activities of
the Congress.
PRESS
Third Floor
• Grand Ballroom - Opening Ceremony, Plenary Sessions
• Trianon Ballroom - Welcome Reception
Working press from print and electronic media may receive
complimentary registration on submission of a copy of press
credentials and a completed registration form. A Press Office
will be available in the Clinton Suite on the 2nd floor.
All meeting room floors being used for the World Congress
are accessible by elevators. Escalators also provide access
between First, Second, and Third Floors.
Press Office Hours:
10:30 am - 7:00 pm
7:00 am - 9:00 pm
6:30 am - 7:00 pm
7:00 am - 2:00 pm
Only registered participants may attend the Scientific Sessions
and the Social Events offered by the World Congress.
All registered participants are entitled to:
GUIDE TO MEETING ROOMS
6
2:00 pm - 6:00 pm
7:00 am - 6:00 pm
6:30 am - 6:00 pm
7:00 am - 12:00 pm
•
March 28-30, 2011
•
7:00 am - 6:00 pm
7:00 am - 6:00 pm
7:00 am - 12:00 pm
New York, NY, USA
•
www.wcidt.org
SCIENTIFIC EXHIBITS
LOST & FOUND
Please return all lost or found items to the Registration Desk.
All items left at the World Congress Lost and Found will be
turned over to New York Hilton upon conclusion of the event.
Scientific Exhibits and Posters will be located inside the
Rhinelander Gallery on the hotel’s second floor. Exhibit and
poster hours are:
Monday, March 28
7:00 am - 6:45 pm
(Poster Session from 5:45 – 6:45 pm)
Tuesday, March 29
6:30 am – 3:00 pm
IN CASE OF EMERGENCY
In the event of any emergency situation, dial extension 5747 or
66 from any house phone or your hotel room. New York Hilton
has security personnel trained in first aid and CPR and a direct
link to NYC emergency services such as ambulance and
paramedics to render aid quickly.
LANGUAGE
The official language of the Congress is English. No simultaneous
translation is provided.
SMOKING
The New York Hilton sleeping rooms, public and meeting space
is 100% smoke-free. There is a “Smoking Oasis” out front of
the Hotel on the main ramp.
WIFI HOTSPOT
A wifi hotspot is offered to participants to remotely access
Internet. The wifi hotspot is located inside the Rhinelander
Ballroom. Funding for the 2nd World Congress wifi hotspot is
graciously provided by Allergan.
PERSONAL INSURANCE COVERAGE
Registration for the World Congress implies that the participant
agrees that neither the Organizing Committee (consisting of the
Advisory and Program Committees), the Weill Cornell Medical
College, the NewYork-Presbyterian Hospital nor the Giovanni
Lorenzini Medical Foundation assume any liability or responsibility
whatsoever. Congress delegates are requested to make their
own arrangements for medical, travel, and personal insurance.
MEALS & COFFEE BREAKS
Continental breakfast and box lunch will be available inside the
Rhinelander Gallery on Monday and Tuesday. Coffee breaks, as
well as Wednesday’s continental breakfast, will be located in
the Grand Ballroom Foyer.
WELCOME RECEPTION
CELLULAR PHONES, BEEPERS & ELECTRONIC DEVICES
In consideration of fellow participants, it is requested that all cell
phones, beepers, pagers, and other electronic devices be
turned off or set to the silent/vibrate mode during all Scientific
Sessions to avoid disruption.
Please join us for this unique opportunity to network with faculty,
guest experts and colleagues. Areas of conversation will be
nestled among tastes and flavors reminiscent of New York
Neighborhoods. Relax and enjoy the music of the best cover
band in New York City ~ Café Wha? ~ with your colleagues
and friends to your favorite funk, classic rock, rhythm and and
meringue dance music.
AMERICANS WITH DISABILITIES STATEMENT
The World Congress wishes to take those steps to ensure that
no individual with a disability is excluded, denied services,
segregated, or otherwise related to differently because of the
absence of auxiliary aids and services identified in the Americans
with Disabilities Act. If any such services are necessary in order
to participate in the Congress, please communicate your needs
in advance.
Trianon Ballroom, Hilton New York
8:00 pm - 10:00 pm
Tickets to the Welcome Reception are available for purchase at
the Registration Desk until 12:00 pm on Monday, March 28. A
ticket and official Congress badge are required for admittance.
The Congress can assist with special needs (e.g. physical,
dietary). For assistance, please stop by the Registration Desk.
CERTIFICATE OF ATTENDANCE
A Certificate of Attendance is available upon request, from the
Registration Desk at the end of the Congress. The request form
may be found in your registration bag.
PROGRAM CHANGES AND MESSAGE BOARD
A Program Change and Message Board is located in the
Registration Area on the 2nd Floor Promenade, where any last
minute changes to the Program will be posted.
BUSINESS CENTER
A fully staffed Business Center is located on the 2nd floor of
the New York Hilton, adjacent to Guest Elevators (next to the
Madison Suite). Services include computer stations, Fax
Services, Copy Machine, and Package Delivery.
Business Center Hours:
Monday - Friday
Saturday & Sunday
CANCELLATION OF THE CONGRESS
In the unlikely event that the 2nd World Congress on
Interventional Therapies for Type 2 Diabetes is abbreviated or
cancelled for any reason whatsoever, the Weill Cornell Medical
College, the NewYork-Presbyterian Hospital and the Giovanni
Lorenzini Medical Foundation and Fondazione Giovanni
Lorenzini reserve the right, in their sole discretion, to unilaterally
terminate the Congress. In such case, the registrant and/or any
funding/supporting organization hereby agrees to waive any
claim against the Weill Cornell Medical College, the NewYorkPresbyterian Hospital and the Giovanni Lorenzini Medical
Foundation and Fondazione Giovanni Lorenzini, for damages or
compensation including but not limited to, fees for registration,
housing, airfare, and incidental charges.
7:00 am - 7:00 pm
9:00 am - 5:00 pm
The Business Center may also be accessed 24 hours a day
using your New York Hilton guest room key. The Business
Center can be contacted though a house phone at Ext. 5212
or by calling (+1) 212-399-1977.
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
7
TAB
Committees & Faculty
BLANK
Back of Tab Page
Congress Advisory Committee
CONGRESS DIRECTOR
M. Sue Kirkman, MD
Chief, GI Metabolic Surgery
Director, Diabetes Surgery Center
Weill Cornell Medical College
NewYork-Presbyterian Hospital
New York, NY USA
Senior Vice President, Medical Affairs
and Community Information
Alexandria, VA USA
Linda Cann, MSEd
Harold E. Lebovitz, MD
Managing Director, Professional Education,
Conventions and International Affairs
Alexandria, VA USA
Professor, Medicine
SUNY Health Science Center at Brooklyn
Brooklyn, NY USA
Fabrizio Michelassi, MD
Lewis Atterbury Stinson Professor and
Chairman
Department of Surgery
Surgeon-in-Chief
NewYork-Presbyterian Hospital/Weill
Cornell Medical Center
New York, NY USA
Ricardo V. Cohen, MD
Co-Director
The Center for the Surgical Treatment of
Morbid Obesity & Metabolic Disorder
Alemão Oswaldo Cruz Hospital
São Paulo, Brazil
David E. Cummings, MD
Alfons Pomp, MD, FRCSC, FACS
Professor, Medicine
Metabolism, Endocrinology & Nutrition
Deputy Director, Diabetes Endocrinology
Research Center
University of Washington School of Medicine
Seattle, WA USA
Leon C. Hirsch Professor of Surgery
Chief, Section Laparoscopic & Bariatric
Surgery
New York, NY USA
Philip Schauer, MD
Antonio M. Gotto, Jr., MD, DPhil
Professor, Surgery
Lerner College of Medicine
Director, Advanced Laparoscopic &
Bariatric Surgery
Cleveland Clinic
The Stephen and Suzanne Weiss Dean
Professor, Medicine
Provost, Medical Affairs
New York, NY USA
Cleveland, OH USA
Lee M. Kaplan, MD, PhD
Paul Zimmet, MD, PhD
Professor, Medicine
Harvard Medical School
Director, MGH Weight Center
Massachusetts General Hospital
Boston, MA USA
Director Emeritus
Director International Research
Baker IDI Heart and Diabetes Institute
Melbourne, Australia
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
9
Program Committee
CONGRESS DIRECTOR
New York, NY USA
CLINICAL TRACK
CO-CHAIR
Phillip Schauer, MD
Professor, Surgery
Bariatric Surgery
Cleveland Clinic
Cleveland, OH USA
CHAIR
Professor, Medicine
Brooklyn, NY USA
RESEARCH TRACK
CHAIR
CO-CHAIR
Professor, Medicine
Research Center
Seattle, WA USA
Lee Kaplan, MD, PhD
Professor, Medicine
Boston, MA USA
CHAIR
CO-CHAIR
David R. Flum, MD, MPH
Director Emeritus
Professor, Surgery
Associate Chair, Research
University of Washington
Seattle, WA USA
POLICY TRACK
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
11
Program Committee
Domenico Accili, MD
Allison B. Goldfine, MD
Professor, Medicine
Director, Diabetes and Endocrinology
Research Center
Columbia University
New York, NY USA
Associate Professor, Medicine
Section Head, Clinical Research
Joslin Diabetes Center
Boston, MA USA
Louis J. Aronne, MD, FACP
M. Sue Kirkman, MD
Clinical Professor, Medicine
Director, Comprehensive Weight Control
Program
New York, NY USA
Alexandria, VA USA
Samuel Klein, MD
Co-Director
Morbid Obesity & Metabolic Disorder
São Paulo, Brazil
William H. Danforth Professor of Medicine
and Nutritional Science
Washington University School of Medicine
St. Louis, MO USA
Rudolph L. Leibel, MD
Christopher J. Murphy Memorial Professor
of Diabetes Research
Co-Director, Naomi Berrie Diabetes
Center;
Head, Division of Molecular Genetics
Columbia University Medical Center
New York, NY USA
John B. Dixon, MBBS, PhD,
FRACGP, FRCPEdin
NHMRC Senior Research Fellow, Vascular
and Hypertension-Obesity Research
Robin S. Goland, MD
Carel W. Le Roux, MB, ChB
Professor of Clinical Medicine and
Pediatrics
Columbia University College of
Physicians & Surgeons
New York, NY USA
12
Reader, Investigative Science
Department of Medicine
Imperial College
London, UK
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
Program Committee
Jesse Roth, MD, FACP
Professor, Medicine
Albert Einstein College of Medicine
Investigator,
Feinstein Institute for Medical Research
Manhasset, NY USA
Timothy E. McGraw, PhD
Professor, Biochemistry
New York, NY USA
Jeffrey I. Mechanick, MD
Endocrinology, Diabetes and Bone Disease
Director, Metabolic Support
Mount Sinai School of Medicine
New York, NY USA
Bruce Wolfe, MD
Professor, Surgery
Oregon Health & Science University
Portland, OR USA
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
13
Distinguished Faculty
Domenico Accili, MD
Louis J. Aronne, MD, FACP
Professor, Medicine
Director, Diabetes & Endocrinology
Research Center
Columbia University
New York, NY USA
Director, Comprehensive Weight Control
Program
New York, NY USA
Ted D. Adams, PhD, MPH
Nicola Basso, MD, FACS
Program Director,
Cardiovascular Genetics,
University of Utah and Health Fitness
Institute
LDS Hospital, Intermountain Healthcare
Salt Lake City, UT USA
Professor, Surgery
Paride Stefanini Department of Surgery
Sapienza University of Rome
Azienda Policlinico Umberto I
Rome, Italy
Richard N. Bergman, PhD
Keck Professor of Medicine
Chair, Department of Physiology and
Biophysics
Keck School of Medicine
University of Southern California
Los Angeles, CA USA
Sir K. George Alberti, MA, DPhil,
BM BCh
Senior Research Investigator, Medicine
Imperial College
London, UK
Zachary T. Bloomgarden, MD
Stephanie A. Amiel, MD
Clinical Professor, Medicine,
Endocrinology, Diabetes, & Bone Disease
New York, NY USA
RD Lawrence Professor, Diabetic Medicine
King’s College
London, UK
Caroline M. Apovian, MD
Professor, Medicine
Boston University School of Medicine
Director, Nutrition and Weight
Management
Boston Medical Center
Boston, MA USA
14
Stacy A. Brethauer, MD
Associate Staff Surgeon
Laparoscopic & Bariatric Surgery
Cleveland Clinic
Cleveland, OH USA
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
Michael S. Brown, MD
W.A. (Monty) Moncrief Distinguished Chair,
Cholesterol & Arteriosclerosis Research
Regental Professor, Molecular Genetics
The University of Texas Southwestern
Medical Center
Dallas, TX USA
1985 Nobel Laureate for Medicine or
Physiology
Tamara Darsow, PhD
Henry Buchwald, MD, PhD
Professor the Lord Ara Darzi of
Denham, PC KBE HonFREng
FmedSci
Vice President Research Programs
Alexandria, VA USA
Professor, Surgery and Biomedical
Engineering
University of Minnesota
Minneapolis, MN USA
Professor, Surgery
Imperial College London
London, UK
Pradeep Chowbey, MD, FACS
Chair, Minimal Access Surgery
Joint Managing Director, Max Institute
of Minimal Access, Metabolic & Bariatric
Surgery
New Delhi, India
Director, Surgery
Specialty Hospital
Goias, Brazil
Ralph DeFronzo, MD
Co-Director
Morbid Obesity and Metabolic Disorder
São Paulo, Brazil
Professor, Medicine
Chief, Diabetes Division
University of Texas Health Science
Center
San Antonio, TX USA
Stefano Del Prato, MD
Professor, Medicine
Research Center
Seattle, WA USA
Professor, Endocrinology and
Metabolism
Chief, Section of Diabetes
University of Pisa
Cisanello Hospital
Pisa, Italy
Aureo Ludovico De Paula, MD
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
15
John B. Dixon, MBBS, PhD,
FRACGP, FRCPEdin
NHMRC Senior Research Fellow,
Vascular and Hypertension-Obesity
Research
Michel Gagner, MD
Clinical Professor, Surgery
Clinique Michel Gagner MD, Inc.
Montreal, QC Canada
Robert H. Eckel, MD
Professor, Medicine
Professor, Physiology and Biophysics
University of Colorado - Anshutz
Medical Campus
Aurora, CO USA
Manoel Galvao Neto, MD
Surgeon & Gastroenterologist
Scientific Coordinator
Gastro Obeso Center
São Paulo, Brazil
Allison B. Goldfine, MD
Section Head, Clinical Research
Joslin Diabetes Center
Boston, MA USA
Ele Ferrannini, MD
Professor, Internal Medicine
University of Pisa
Pisa, Italy
Joseph L. Goldstein, MD
Julie and Louis A. Beecherl Distinguished Chair in Biomedical Science
Regental Professor, Molecular Genetics
The University of Texas Southwestern
Medical Center
Dallas, TX USA
1985 Nobel Laureate for Medicine or
Physiology
David R. Flum, MD, MPH
Professor, Surgery
Associate Chair, Research
Seattle, WA USA
Antonio M. Gotto, Jr. , MD, DPhil
John Funder, MD, PhD, FRACP,
FRCP
The Stephen and Suzanne Weiss Dean
Professor, Medicine
Provost, Medical Affairs
New York, NY USA
Professor, Medicine
Prince Henry's Institute
Clayton, Australia
16
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
Jan Willem M. Greve, MD, PhD
Shashank R. Joshi, MBBS, MD,
DM
Professor, Surgery
Chair, Department of Surgery
Atrium Medical Center Parkstad
Heerleen, Limburg The Netherlands
Professor, Consultant
Grant Medical College and Sir JJ Group
of Hospitals
Mumbai, India
Peter Hill, MD, PhD
Steven H. Kahn, MB, ChB
Corporate Medical Director
Medical Administration Department
Hamad Medical Corporation
Doha, Qatar
Professor, Medicine
VA Puget Sound Health Care System
Seattle, WA USA
Lee Kaplan, MD, PhD
Bjorn Hofmann, MSc, PhD
Professor, Medicine
Boston, MA USA
Professor, Medical Ethics
Institute for Health and Society
University of Oslo
Oslo, Norway
Catherine Keating, MPH
Senior Research Fellow
Deakin Health Economics, Faculty of
Health
Deakin University
Jens Juul Holst, MD
Professor, Medical Physiology
Institute of Biomedical Sciences
Copenhagen, Denmark
Linong Ji, MD
Co-Director, Peking University Diabetes
Center
Director, Department Of Endocrinology
And Metabolism, Peking University
People’s Hospital
President, Chinese Diabetes Society
Vice President,
Chinese Endocrinologist Association
Beijing, China
M. Sue Kirkman, MD
Alexandria, VA USA
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
17
Samuel Klein, MD
Carel W. Le Roux, MD, PhD
William H. Danforth Professor of
Medicine and Nutritional Science
Washington University School of
Medicine
St Louis, MO USA
Reader, Investigative Science
Department of Medicine
Imperial College
London, UK
Judith Korner, MD, PhD
Director, Weight Control Center
New York, NY USA
Professor, Medicine
Brooklyn, NY USA
Frank Lefevre, MD
Senior Scientist, BCBSA Technology
Evaluation Center
Northwestern Feinberg School of
Medicine
Chicago, IL USA
Blandine B. Laferrere, MD
Columbia University College of Physicians
and Surgeons
New York, NY USA
Rudolph L. Leibel, MD
Muffazal Abdulkader Lakdawala, MD
Christopher J. Murphy Memorial Professor
of Diabetes Research
Co-Director, Naomi Berrie Diabetes Center
Head, Division of Molecular Genetics
New York, NY USA
Chief, Minimal Access & Bariatric Surgery
Department
Centre for Obesity and Diabetes Support
Saifee Hospital
Mumbai, India
David Lautz, MD
Ruth E. Ley, PhD
Director of Bariatric Surgery
Harvard Medical School, Brigham and
Women's Hospital
Boston, MA USA
18
Assistant Professor, Microbiology
Cornell University
Ithaca, NY USA
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
Xavier Pi-Sunyer, MD
Rui Li, PhD
Chief of Endocrinology and
Professor of Medicine
St. Luke’s Roosevelt Hospital
Columbia University
New York, NY USA
Health Economist
Centers for Disease Control and
Prevention
Atlanta, GA USA
Alfons Pomp, MD, FRCSC,
FACS
Leon C. Hirsch Professor of Surgery
Chief, Section Laparoscopic &
Bariatric Surgery
New York, NY USA
Timothy E. McGraw, PhD
Professor, Biochemistry
New York, NY USA
Jeffrey I. Mechanick, MD
Clinical Professor, Medicine,
Endocrinology, Diabetes and Bone
Disease
Director, Metabolic Support
New York, NY USA
Walter J. Pories, MD, FACS
Professor, Surgery, Biochemistry
and Exercise and Sports Science
East Carolina University
Greenville, NC USA
Jesse Roth, MD, FACP
Geltrude Mingrone, MD, PhD
Professor, Medicine
Albert Einstein College of Medicine
Investigator, Feinstein Institute for
Medical Research
Manhasset, NY USA
Professor, Internal Medicine,
Endocrinology
Catholic University of the Sacred Heart
Rome, Italy
John J. Moore, DO, FAAFP
New York, NY USA
Patient Management Medical Director
for the Northeast Region
AETNA
Blue Bell, PA USA
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
19
Lars V. Sjöström, MD, PhD
Mohammed Fathy Saoud, PhD
Professor Emeritus, SOS Secretariate
Internal Medicine
Sahlgrenska University Hospital
Göteborg, Sweden
President
Qatar Foundation
Doha, Qatar
Phillip Schauer, MD
Professor, Surgery
Bariatric Surgery
Cleveland Clinic
Myrlene Staten, MD
Senior Advisor, Diabetes Translational
Research
NIDDK, National Institutes of Health
Bethesda, MD USA
Cleveland, OH USA
Harvey J. Sugerman, MD
Gary Schwartz, PhD
Professor of Medicine & Neuroscience
Albert Einstein College of Medicine of
Yeshiva University
Bronx, NY USA
Emeritus Professor, Surgery
Editor-in-Chief, Surgery for Obesity and
Related Diseases
Virginia Commonwealth University
Richmond, VA USA
Randy J. Seeley, PhD
Sean D. Sullivan, PhD
Director, Cincinnati Diabetes Obesity Center
University of Cincinnati
Donald C. Harrison Endowed Professor
in Medicine
Professor, Health Sciences and
Department of Pharmacy
Associate Dean for Research
University of Washington School
of Pharmacy
Seattle, WA USA
Metabolic Diseases Institute
Cincinnati, OH USA
Gerald I. Shulman, MD, PhD
Investigator, Howard Hughes Medical Institute
Professor, Physiological Chemistry,
Medicine (Endocrinology) and Cellular &
Molecular Physiology
Associate Director, Diabetes-Endocrinology
Research Center
Associate Director, Medical Scientist Training
Program
Yale University School of Medicine
New Haven, CT USA
20
Tess Van Der Merwe, MBChB, PhD
Director
Centres of Excellence for Metabolic
Medicine and Surgery
Gauteng, South Africa
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
Bruce Wolfe, MD, FACS
Director Emeritus
Professor, Surgery
Oregon Health & Science University
Portland, OR USA
Carol H. Wysham, MD
Clinical Associate Professor, Medicine
University of Washington School of
Medicine
Section Head, Rockwood Center for
Diabetes & Endocrinology
Rockwood Clinic
Spokane, WA USA
Mahmoud Ali Zirie, MD
Professor, Medicine
Head, Endocrinology Diabetes Division
Doha, Qatar
James Young, MD
Professor, Medicine
Executive Dean
Institute Chair
Endocrinology & Metabolism Institute
Cleveland Clinic
Cleveland, OH USA
Added late:
David H. Finley, MD, FACS
Chief Medical Officer
Enterprise Affordability
CIGNA Healthcare
White Plains, NY USA
Abdul Latif Mohamad Al-Khal, MD, ABIM, ABID
Sr. Consultant, Infectious Diseases
Chairman, Department of Medicine
Director, Department of Medical Education
Doha, Qatar
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
21
Guest Experts
In addition to contributing to the scholarship of the audience, the presence of Guest Experts is meant to facilitate a lively
discussion and debate throughout the course of the World Congress. Guest Experts will also steer group discussion during
breakout sessions on Tuesday, March 29th. We would like to thank the following individuals for providing a unique
perspective to the emerging field of interventional diabetology:
Vince Aguirre, MD .
Luiz Vicente Berti, MD .
Brazil
. . . . . . . . . . . . . . . . . . . . . . . . . . .
Morris J. Birnbaum, MD, PhD .
. . . . . . . . . . . . . . . . . . . . . .
USA
Robin Blackstone, MD, FACS .
. . . . . . . . . . . . . . . . . . . . . .
USA
. . . . . . . . . . . . . . . . . . . . . . . . .
Chile
. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
USA
Camilo Boza, MD, FACS .
David J. Brillon, MD .
Marco Castagneto, MD .
. . . . . . . . . . . . . . . . . . . . . . Taiwan
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
USA
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chile
Gregory F. Dakin, MD .
Alex Escalona, MD .
. . . . . .
USA
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
Italy
Mathias A. Fobi, MD, FACS, FASMBS, FICS, FACN .
Paolo Gentileschi, MD .
Giovanni Ghirlanda, MD .
Ramen Goel, MD .
Neil E. Hutcher, MD, FACS .
Kazunori Kasama, MD, FACS .
John G. Kral, MD, PhD, FACS .
. . . . . . . . . . . . . . . . . . . .
USA
. . . . . . . . . . . . . . . . . . . . . .
USA
. . . . . . . . . . . . . . . . . . . . . . . . . .
Bassem M. Masri, MD .
. . . . . . . . . . . . . . . . . . . . . . . . . . .
Naina Sinha, MD .
. . . . . . . . . . . . . . . . . . . . . . . . . . .
Taiwan
USA
France
. . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Italy
Brazil
. . . . . . . . . . . . . . . . . . . . . . . . . .
USA
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
USA
April D. Strader, PhD .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Richard Stubbs, MD, FRCS, FRACS .
Michel Suter, MD .
USA
Japan
Wei-Jei Lee, MD, PhD .
Mitch Roslin, MD, FACS .
USA
. . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
Subhash Kini, MD, FRCS, FACS .
Antonio E. Pontiroli, MD .
India
. . . . . . . . . . . . . . . . . . . . . . . .
William B. Inabnet, III, MD, FACS .
Francois Pattou, MD .
Italy
. . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Almino Ramos, MD .
Italy
. . . . . . . . . . . . . . . . . . . . . . . . . . .
Lee-Ming Chuang, MD, PhD .
. . . . . . . . . . .
Switzerland
. . . . . . . . . . . . . . . . . . . . . . . . . .
Antonio José Torres, MD, PhD .
Jonathan A. Waitman, MD .
USA
New Zealand
. . . . . . . . . . . . . . . . . . . . . . . . . .
Julio Teixeira, MD, FACS .
22
USA
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
USA
. . . . . . . . . . . . . . . . . . . . .
Spain
. . . . . . . . . . . . . . . . . . . . . . . .
USA
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
TAB
Scientific Program
BLANK
Back of Tabe Page
Program At-A-Glance
MONDAY, MARCH 28, 2011
7:00 am - 8:00 am
Continental Breakfast (Rhinelander Gallery)
7:00 am - 9:00 pm
Registration Open (2nd Floor Promenade)
7:00 am - 6:45 pm
Exhibits and Posters (Rhinelander Gallery)
8:00 am - 8:20 am
Opening Ceremony (Grand Ballroom)
8:20 am - 8:35 am
Introduction of the World Congress: Scope and Methods
F. Rubino (New York, NY USA)
CLINICAL TRACK SESSION I (Grand Ballroom)
8:35 am - 10:50 am
Clinical Outcomes of Conventional and Surgical Treatments for T2DM
10:50 am - 11:10 am
Refreshment Break (Grand Ballroom Foyer)
POLICY TRACK SESSION I (Grand Ballroom)
The International Diabetes Federation (IDF) Position Statement on Interventional
11:10 am - 12:30 pm
Treatments of Type 2 Diabetes
12:30 pm - 1:30 pm
Lunch (Rhinelander Gallery)
CLINICAL TRACK SESSION II (Grand Ballroom)
1:30 pm - 3:00 pm
CV Risk Reduction and Survival in Patients with Diabetes: Medical versus Surgical Therapy
3:00 pm - 3:20 pm
CLINICAL TRACK SESSION III (Grand Ballroom)
3:20 pm - 5:45 pm
Diabetes Surgery: Indications, Choice of Procedure & Peri-Operative Management
5:45 pm - 6:45 pm
Poster Session (Rhinelander Gallery)
8:00 pm - 11:00 pm
Welcome Reception (Trianon Ballroom)
TUESDAY, MARCH 29, 2011
6:30 am - 7:30 am
Continental Breakfast (Rhinelander Gallery)
6:30 am - 7:00 pm
6:30 am - 3:00 pm
Exhibits and Posters (Rhinelander Gallery)
RESEARCH TRACK SESSION I (Grand Ballroom)
7:30 am - 9:40 am
Mechanisms of Action of Surgery
RESEARCH TRACK SESSION II (Grand Ballroom)
Novel Experimental Approaches for Diabetes/Obesity
9:40 am - 11:10 am
11:10 am - 11:30 am
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
23
(cont’d)
RESEARCH TRACK SESSION III (Grand Ballroom)
11:30 am - 1:00 pm
Defining Priorities for Clinical Research in Metabolic/Diabetes Surgery
1:00 pm - 2:00 pm
Lunch (Rhinelander Gallery)
POLICY TRACK SESSION II (Grand Ballroom)
2:00 pm - 3:00 pm
Global Burden of Diabetes and Resource Availability for Interventional Approaches
POLICY TRACK SESSION III (Grand Ballroom)
3:00 pm - 4:30 pm
Cost Effectiveness of Diabetes Surgery: Implications for Public and Private Health
Insurance
4:30 pm - 4:50 pm
BREAKOUT SESSIONS AND WORKSHOPS (Sutton Complex Rooms)
4:50 pm - 6:50 pm
Breakout Sessions
Clinical (Sutton North/Beekman)
Research (Sutton Center)
Policy (Sutton South/Regent)
WEDNESDAY, MARCH 30, 2011
7:00 am - 2:00 pm
7:00 am - 8:00 am
Continental Breakfast (Grand Ballroom Lobby)
KEYNOTE LECTURE (Grand Ballroom)
8:00 am - 9:00 am
Surviving Starvation: Essential Role of the Ghrelin-Growth Hormone Axis
M.S. Brown (Dallas, TX USA)
J.L. Goldstein (Dallas, TX USA)
RESEARCH TRACK SESSION IV (Grand Ballroom)
9:00 am - 10:40 am
The Role of the Gut in the Physiology and Pathophysiology of Obesity and Diabetes
10:40 am - 11:00 am
PANEL DISCUSSION (Grand Ballroom)
The GI tract: Could it be the missing link between obesity and diabetes?
11:00 am - 12:00 pm
EXECUTIVE SUMMARIES/TAKE HOME MESSAGE (Grand Ballroom)
12:00 pm - 1:15 pm
Presentation of Executive Summaries and Conclusions
1:20 pm
24
World Congress Adjourns
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
Scientific Program
MONDAY, MARCH 28, 2011
7:00 am - 8:00 am
CONTINENTAL BREAKFAST (Rhinelander Gallery)
8:00 am - 8:20 am
Grand Ballroom
Opening Ceremony
8:20 am - 8:35 am
Grand Ballroom
Introduction of the World Congress: Scope and Methods
CLINICAL TRACK SESSION I
8:35 am - 10:50 am
Grand Ballroom
Clinical Outcomes of Conventional and Surgical Treatments for T2DM
Chairs: W. Pories (Greenville, NC USA)
8:35 am - 8:55 am
•
H.E. Lebovitz (Brooklyn, NY USA)
Glycemic and metabolic control with current pharmacologic treatments
S. Del Prato (Pisa, Italy)
8:55 am - 9:15 am
Glycemic and metabolic outcomes with bariatric/metabolic surgery: overview
P. Schauer (Cleveland, OH USA)
9:15 am - 9:30 am
Long-term prevention and remission of diabetes after bariatric surgery in the SOS study
L. Sjöström (Göteborg, Sweden)
9:30 am - 9:45 am
Safety profiles of pharmaceutical approaches
9:45 am - 10:00 am
Safety profiles of surgical approaches: short and long term
B.M. Wolfe (Portland, OR USA)
10:00 am - 10:50 am
Panel Discussion
Panelists: S.A. Amiel (London, UK), Z.T. Bloomgarden (New York, NY USA), J. Dixon (Melbourne,
Australia), A. Pomp (New York, NY USA), H. Buchwald (Minneapolis, MN USA), A.B. Goldfine (Boston, MA
USA), K.G. Alberti (London, UK), J.I. Mechanick (New York, NY USA), X. Pi-Sunyer (New York, NY USA)
10:50 am - 11:10 am
COFFEE BREAK (Grand Ballroom Foyer)
POLICY TRACK SESSION I
11:10 am - 12:30 pm
Grand Ballroom
The International Diabetes Federation (IDF) Position Statement on Interventional Treatments of Type 2
Diabetes
Chairs: J. Dixon (Melbourne, Australia)
11:10 am - 11:20 am
•
K.G. Alberti (London, UK)
Existing guidelines for surgical treatment of obesity and diabetes (NIH, DSS, ADA)
L.M. Kaplan (Boston, MA USA)
11:20 am - 11:40 am
The IDF position statement on interventional therapies for type 2 diabetes
P. Zimmet (Melbourne, Australia)
11:40 am - 12.30 pm
Panel Discussion
Panelists: C. Wysham (ADA) (Seattle, WA USA), J.I. Mechanick (AACE) (New York, NY USA), S.A. Amiel
(Diabetes UK) (London, UK), X. Pi-Sunyer (NHLBI) (New York, NY USA), A.M. Gotto (New York, NY USA),
F. Rubino (New York, NY USA), R.H. Eckel (Aurora, CO USA)
12:30 pm - 1:30 pm
26
LUNCH BREAK (Rhinelander Gallery)
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
Scientific Program
CLINICAL TRACK SESSION II
1:30 pm - 3:00 pm
Grand Ballroom
CV Risk Reduction and Survival in Patients with Diabetes: Medical versus Surgical Therapy
Chairs: A.M. Gotto (New York, NY USA)
1:30 pm - 1:50 pm
•
K.G. Alberti (London, UK)
CV risk, CVD and diabetes-related mortality: impact of pharmacologic approaches
R.H. Eckel (Aurora, CO USA)
1:50 pm - 2:05 pm
Long-term (20 years) impact of bariatric surgery on CV risk and CVD: an update from the
SOS study
L. Sjöström (Göteborg, Sweden)
2:05 pm - 2:15 pm
The impact of bariatric/metabolic surgery on CV risk and long-term survival
T.D. Adams (Salt Lake City, UT USA)
2:15 pm - 3:00 pm
Panel Discussion
Panelists: R. DeFronzo (San Antonio, TX USA), E. Ferrannini (Pisa, Italy), S.R. Joshi (Mumbai, India), S.E.
Kahn (Seattle, WA USA), J. Young (Cleveland, OH USA), H.J. Sugerman (Richmond, VA USA), W. Pories
(Greenville, NC USA)
3:00 pm - 3:20 pm
CLINICAL TRACK SESSION III
3:20 pm - 5:45 pm
Grand Ballroom
Diabetes Surgery: Indications, Choice of Procedure & Peri-Operative Management
Chairs: L. Aronne (New York, NY USA)
3:20 pm - 3:35 pm
•
J. Young (Cleveland, OH USA)
Predicting factors of diabetes control/reasonable criteria for surgical indication
J. Korner (New York, NY USA)
3:35 pm - 3:50 pm
Preoperative management of diabetic patients
C.M. Apovian (Boston, MA USA)
3:50 pm - 4:05 pm
Which surgical procedure is best? Summary of available evidence from comparative
clinical studies in high and low BMI patients
H.J. Sugerman (Richmond, VA USA)
4:05 pm - 4:40 pm
Panel Discussion
Panelists: H.E. Lebovitz (Brooklyn, NY USA), S.R. Joshi (Mumbai, India), J.I. Mechanick (New York, NY
USA), J. Dixon (Melbourne, Australia), M. Gagner (Montreal, QC, Canada), R.V. Cohen (São Paulo, Brazil)
4:40 pm - 4:55 pm
Postoperative management of obese and diabetic patients; the role of
integrated/multimodality therapies
L. Aronne (New York, NY USA)
4:55 pm - 5:15 pm
A rational and physiologic approach to the management of diabetes after surgery
R. DeFronzo (San Antonio, TX USA)
5:15 pm - 5:45 pm
Panel Discussion
Panelists: C. Wysham (Seattle, WA USA), S.E. Kahn (Seattle, WA USA), R.N. Bergman (Los Angeles, CA
USA), L. Ji (Beijing, China), S. Del Prato (Pisa, Italy)
5:45 pm - 6:45 pm
POSTER SESSION (Rhinelander Gallery)
8:00 pm
WELCOME RECEPTION (Trianon Ballroom)
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
27
Scientific Program
6:30 am - 7:30 am
CONTINENTAL BREAKFAST (Rhinelander Gallery)
RESEARCH TRACK SESSION I
7:30 am - 9:40 am
Grand Ballroom
Mechanisms of Action of Surgery
Chairs: L.M. Kaplan (Boston, MA USA)
7:30 am - 7:45 am
•
S.E. Kahn (Seattle, WA USA)
Mechanisms of Weight Loss: beyond restriction and malabsorption
R.J. Seeley (Cincinnati, OH USA)
7:45 am - 8:00 am
Effect of GI surgery on insulin secretion/sensitivity
S. Klein (St. Louis, MO USA)
8:00 am - 8:15 am
Effects of GI surgery on food choices and energy expenditure
C.W. Le Roux (London, UK)
8:15 am - 8:30 am
Effects of GI surgery on glucose homeostasis
J.J. Holst (Copenhagen, Denmark)
8:30 am - 9:00 am
8:30 am - 8:45 am
8:45 am - 9:00 am
Debate: Diabetes control by GI surgery is explained by weight-independent mechanisms
Yes: D.E. Cummings (Seattle, WA USA)
No: E. Ferrannini (Pisa, Italy)
9:00 am - 9:40 am
Panel Discussion: Weight independent mechanisms of diabetes control: weighing the
evidence
Panelists: J. Korner (New York, NY USA), G. Mingrone (Rome, Italy), R.N. Bergman (Los Angeles, CA USA),
R. DeFronzo (San Antonio, TX USA), B.B. Laferrere (New York, NY USA), G.J. Schwartz (New York, NY USA)
RESEARCH TRACK SESSION II
9:40 am - 11:10 am
Grand Ballroom
Novel Experimental Approaches for Diabetes/Obesity
Chairs: H. Buchwald (Minneapolis, MN USA)
9:40 am - 9:55 am
•
S. Klein (St. Louis, MO USA)
Novel GI surgical procedures (DJB and Ileal Interposition: alone and with associated sleeve
gastrectomy)
R.V. Cohen (São Paulo, Brazil)
9:55 am - 10:10 am
Endoluminal procedures for obesity/diabetes
S.A. Brethauer (Cleveland, OH USA)
10:10 am - 10:25 am
Endoluminal devices for obesity/diabetes
L.M. Kaplan (Boston, MA USA)
10:25 am - 10:40 am
Pacing/GI electric stimulation for diabetes
10:40 am - 11:10 am
Panel Discussion
Panelists: J.W.M. Greve (Heerleen, Netherlands), M. Galvao Neto (São Paulo, Brazil), A. De Paula (Goiania,
Brazil), W. Pories (Greenville, NC USA), J. Funder (Clayton, Australia), S.R. Joshi (Mumbai, India)
11:10 am - 11:30 am
28
COFFEE BREAK (Grand Ballroom Lobby)
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
Scientific Program
RESEARCH TRACK SESSION III
11:30 am - 1:00 pm
Grand Ballroom
Defining Priorities for Clinical Research in Metabolic/Diabetes Surgery
Chairs: A.B. Goldfine (Boston, MA USA)
11:30 am - 11:45 am
•
J. Roth (Manhasset, NY USA)
Clinical trials in diabetes surgery: overview of ongoing trials; challenges for study design,
practical issues in surgical trials
A.B. Goldfine (Boston, MA USA)
11:45 am - 12:00 pm
Clinical trials in diabetes surgery: ethical aspects
B.M. Hofmann (Oslo, Norway)
12:00 pm - 12:15 pm Advantages and disadvantages of each design, multisite vs consortium model for large
clinical trials
12:15 pm - 1:00 pm
Panel Discussion: Priorities for clinical research in diabetes surgery; costs/funding, ethical
aspects
Panelists: P. Schauer (Cleveland, OH USA), R. DeFronzo (San Antonio, TX USA), J. Korner (New York,
NY USA), D. Lautz (Boston, MA USA), M. Staten (Bethesda, MD USA), F. Saoud (Doha, Qatar), T. Darsow
(Alexandria, VA USA)
1:00 pm - 2:00 pm
LUNCH BREAK (Rhinelander Gallery)
POLICY TRACK SESSION II
2:00 pm - 3:00 pm
Grand Ballroom
Global Burden of Diabetes and Resource Availability for Interventional Approaches
Chairs: P. Zimmet (Melbourne, Australia)
2:00 pm - 2:15 pm
•
P. Chowbey (New Delhi, India)
The global epidemiology of diabetes
2:15 pm - 2:30 pm
The global costs of diabetes
R. Li (Atlanta, GA USA)
2:30 pm - 3:00 pm
Panel Discussion: Specific regional challenges for diabetes prevention and treatment
Panelists: L. Ji (Beijing, China), J. Funder (Clayton, Australia), T. Van Der Merwe (Pretoria, South Africa),
A. Darzi (London, UK), M. Ali Zirie (Doha, Qatar), R. Li (Atlanta, GA USA)
POLICY TRACK SESSION III
3:00 pm - 4:30 pm
Grand Ballroom
Cost Effectiveness of Diabetes Surgery: Implications for Public and Private Health Insurance
Chairs: A. Darzi (London, UK)
3:00 pm - 3:15 pm
•
D. Flum (Seattle, WA USA)
Review of what we know about cost-effectiveness of bariatric surgery with special regard
to patients with diabetes
C. Keating (Burwood, Australia)
3:15 pm - 3:30 pm
How governments consider evidence on cost-effectiveness
S.D. Sullivan (Seattle, WA USA)
3:30 pm - 3:45 pm
How payers consider the evidence of cost and effectiveness
F. Lefevre (Chicago, IL USA)
3:45 pm - 4:30 pm
Panel Discussion: Simply cost-effective? Reconciling cost-evaluations related to diabetes
interventions
Panelists: R. Li (Atlanta, GA USA), C. Keating (Burwood, Australia), S.D. Sullivan (Seattle, WA USA),
F. Lefevre (Chicago, IL USA), J.J. Moore (Blue Bell, PA USA)
4:30 pm - 4:50 pm
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
29
Scientific Program
(continued)
BREAKOUT SESSIONS AND WORKSHOPS
4:50 pm - 6:50 pm
Breakout Sessions for Interactive Discussion and Preparation of Executive Summary
CLINICAL TRACK
4:50 pm - 6:50 pm
Sutton North/Beekman
Defining appropriate surgical candidates and good clinical practice for perioperative management and
post-operative follow-up
Chairs: H.E. Lebovitz (Brooklyn, NY USA)
4:50 pm - 5:25 pm
4:50 pm - 4:55 pm
•
P. Schauer (Cleveland, OH USA)
Workshop A: Defining appropriate surgical candidates for diabetes surgery
Who should be referred for surgical treatment of diabetes?
4:55 pm - 5:10 pm
Expert Panel Comments
W.J. Pories (Greenville, NC USA), L.J. Aronne (New York, NY USA), R. DeFronzo (San Antonio, TX USA),
J. Young (Cleveland, OH USA)
5:10 pm - 5:25 pm
5:25 pm - 6:20 pm
Q&A: Guest Experts and Audience
Interactive Opinion Polls
Guest Experts: M. Castagneto, G. Ghirlanda,
N. Hutcher, M. Suter, J. Texteira,
Workshop B: Defining ideal indications for each surgical procedure
5:25 pm - 5:50 pm
Which patients should undergo...
Biliopancreatic Diversion/DS - A. Pomp (New York, NY USA)
Sleeve Gastectomy - M. Gagner (Montreal, QC, Canada)
Gastric Bypass - P. Schauer (Cleveland, OH USA)
Gastric Banding - J.B. Dixon (Melbourne, Australia)
Novel GI Procedures: To re-route or not to re-route the bowel? - R.V. Cohen (São Paulo, Brazil)
5:50 pm - 6:05 pm
H. Buchwald (Minneapolis, MN USA), P. Chowbey (New Delhi, India), A.L. De Paula (Goiânia, Brazil),
J.W.M. Greve (Heerleen, Netherlands)
6:05 pm - 6:20 pm
6:20 pm - 6:50 pm
6:20 pm - 6:25 pm
Guest Experts: C. Boza, G. Dakin,
K. Kasama, S. Kini, WJ. Lee
Workshop C: Defining and measuring success of surgical treatment of diabetes
Definition of success and appropriate clinical measures to assess outcomes of surgical
treatment
J.I. Mechanick (New York, NY USA)
6:25 pm - 6:40 pm
H.J. Sugerman (Richmond, VA USA), J. Korner (New York, NY USA), R. DeFronzo (San Antonio, TX USA),
S.R. Joshi (Mumbai, India)
6:40 pm - 6:50 pm
Guest Experts: M. Fobi, P. Gentileschi, N. Sinha, J. Waitman
30
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
Scientific Program
4:50 pm - 6:50 pm
RESEARCH TRACK
4:50 pm - 6:50 pm
Sutton Center
Defining priorities for clinical trials and investigations on mechanisms of action of surgery
Chairs: L. Kaplan (Boston, MA USA)
4:50 pm - 5:35 pm
4:50 pm - 5:00 pm
•
D.E. Cummings (Seattle, WA USA)
Workshop A: Defining mechanisms of action of surgery and their implications for future
diabetes therapies and understanding of disease mechanisms
Mechanisms of action of metabolic surgery: what is clear and what is not
Lessons for future pharmacologic therapies
Lessons about diabetes/obesity pathophysiology
L. Kaplan (Boston, MA USA)
5:00 pm - 5:20 pm
G. Mingrone (Rome, Italy), G. Schwartz (Bronx, NY USA), B.B. Laferrere (New York, NY USA),
R.N. Bergman (Los Angeles, CA USA)
5:20 pm - 5:35 pm
5:35 pm - 6:10 pm
5:35 pm - 5:40 pm
Guest Experts: V. Aguirre, M. Birnbaum,
J. Kral, F. Pattou, A. Strader, R. Stubbs
Workshop B: Defining appropriate methods of innovation in bariatric and metabolic
surgery and novel interventional treatments for diabetes
Defining proper clinical and pre-clinical assessment of new surgical procedures and devices
C.W. Le Roux (London, UK)
5:40 pm - 5:55 pm
B.M. Hofmann (Oslo, Norway), M.Galvao Neto (São Paulo, Brazil), S. Klein (St. Louis, MO USA), S. Del Prato
(Pisa, Italy)
5:55 pm - 6:10 pm
6:10 pm - 6:50 pm
6:10 pm - 6:15 pm
Guest Experts: L. Berti, A. Escalona,
A. Ramos, A. Torres
Workshop C: Defining priorities for clinical research
Diabetes surgery: the most compelling clinical issues that require priority testing by
randomized clinical trials
6:15 pm - 6:35 pm
A.B. Goldfine (Boston, MA USA), M. Staten (Bethesda, MD USA), S.H. Kahn (Seattle, WA USA),
X. Pi-Sunyer (New York, NY USA), D. Lautz (Boston, MA USA)
6:35 pm - 6:50 pm
Guest Experts: D. Brillon, W. Inabnet
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
31
Scientific Program
(continued)
4:50 pm - 6:50 pm
POLICY TRACK
4:50 pm - 6:50 pm
Sutton South/Regent
Proposing practical solutions to improve access to surgery when indicated
Chairs: P. Zimmet (Melbourne, Australia)
4:50 pm - 5:50 pm
•
Workshop A: Creating a pathway to reconcile professional guidelines
5:00 pm - 5:40 pm
Panel Discussion/Round Table with official representatives of the following organizations:
NHLBI Obesity Guidelines (X. Pi-Sunyer, New York, NY USA), ADA (M.S. Kirkman, Alexandria, VA USA),
AACE (J.I. Mechanick, New York, NY USA), ASMBS (B. Wolfe, Portland, OR USA), TOS (C.M. Apovian,
Boston, MA USA), SBCBM (R.V. Cohen, São Paulo, Brazil), SICOB (N. Basso, Rome, Italy), IFSO
(M. Lakdawala, Mumbai, India)
5:40 pm - 5:50 pm
5:50 pm - 6:50 pm
Workshop B: Payer perspectives: creating a pathway for policymakers and payers to
reconcile approaches
6:00 pm - 6:40 pm
Panel Discussion/Round Table
F. Lefevre (Chicago, IL USA), S.D. Sullivan (Seattle, WA USA), J. Funder (Clayton, Australia), L. Ji (Beijing,
China), C. Keating (Buswood, Australia), T. Van Der Merwe (Pretoria, South Africa), P. Hill (Doha, Qatar),
J.J. Moore (Blue Bell, PA USA) , A.L.M. Al-Khal (Doha, Qatar),
6:40 pm - 6:50 pm
D. Finley CIGNA (White Plains, NY)
Guest Experts: R. Blackstone, LM. Chuang, R. Goel, M. Roslin
32
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
Scientific Program
7:00 am - 8:00 am
CONTINENTAL BREAKFAST (Grand Ballroom Foyer)
KEYNOTE LECTURE
8:00 am - 9:00 am
8:00 am - 9:00 am
Grand Ballroom
Surviving Starvation: Essential Role of the Ghrelin-Growth Hormone Axis
M.S. Brown (Dallas, TX USA)
J.L. Goldstein (Dallas, TX USA)
The Nobel Prize in Physiology or Medicine 1985 was awarded jointly to Michael S. Brown and
Joseph L. Goldstein “for their discoveries concerning the regulation of cholesterol metabolism”.
RESEARCH TRACK SESSION IV
9:00 am - 10:40 am
Grand Ballroom
The role of the gut in the physiology and pathophysiology of obesity and diabetes
Chairs: T.E. McGraw (New York, NY USA)
9:00 am - 9:20 am
•
D. Accili (New York, NY USA)
Conventional paradigm of the pathophysiology of obesity
R.L. Leibel (New York, NY USA)
9:20 am - 9:40 am
Conventional paradigm of the pathophysiology of diabetes
R.N. Bergman (Los Angeles, CA USA)
9:40 am - 10:00 am
The physiologic role of the gut in energy and glucose homeostasis
J.J. Holst (Copenhagen, Denmark)
10:00 am - 10:20 am
The role of intestinal microbiota in insulin resistance, obesity/diabetes
R.E. Ley (Ithaca, NY USA)
10:20 am - 10:40 am
Impaired GI physiology in individuals with diabetes/obesity
10:40 am - 11:00 am
PANEL DISCUSSION
11:00 am - 12:00 pm
Grand Ballroom
The GI tract: could it be the missing link between obesity and diabetes?
11:00 am - 11:05 am
11:05 pm - 12:00 pm
Introduction
Panel Discussion
M.S. Brown (Dallas, TX USA), J.L. Goldstein (Dallas, TX USA), G. Shulman (New Haven, CT USA),
S. Klein (St. Louis, MO USA), R. DeFronzo (San Antonio, TX USA), S.E. Kahn (Seattle, WA USA),
J. Roth (Manhasset, NY USA), L.M. Kaplan (Boston, MA USA)
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
33
Scientific Program
(continued)
EXECUTIVE SUMMARIES/TAKE HOME MESSAGE
12:00 pm - 1:15 pm
Grand Ballroom
Presentation of Executive Summaries and Conclusions
Chairs: M. Sue Kirkman (Alexandria, VA USA)
12:00 pm - 12:12 pm
•
W. Pories (Greenville, NC USA)
Clinical Practice
12:12 pm - 12:24 pm
Priorities for Clinical Research
12:24 pm - 12:36 pm
Reconciling Guidelines
12:36 pm - 12:48 pm
Public Health Policies
12:48 pm - 1:00 pm
The evolving paradigm of diabetes pathogenesis
J. Roth (Manhasset, NY USA)
34
1:00 pm - 1:15 pm
INTERACTIVE OPINION POLLS
1:15 pm - 1:20 pm
CLOSING REMARKS
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
Faculty Index
A
Accili, Domenico . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Adams, Ted D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Alberti, K. George . . . . . . . . . . . . . . . . . . . . . . . . 26, 27
Amiel, Stephanie A. . . . . . . . . . . . . . . . . . . . . . . . . . 26
Apovian, Caroline M. . . . . . . . . . . . . . . . . . . . . . . 27, 32
Aronne, Louis . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 30
L
Laferrere, Blandine B. . . . . . . . . . . . . . . . . . . . . . 28, 31
Lakdawala, M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Lautz, David B. . . . . . . . . . . . . . . . . . . . . . . . . . 29, 31
Lebovitz, Harold E. . . . . . . . . . . . . . . . 26, 27, 28, 30, 34
Lefevre, Frank . . . . . . . . . . . . . . . . . . . . . . . . . . 29, 32
Leibel, Rudolph L. . . . . . . . . . . . . . . . . . . . . . . . . . . 33
LeRoux, Carel W. . . . . . . . . . . . . . . . . . . . . . . . . 28, 31
Ley Ruth, E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Li, Rui . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
B
Basso, Nicola . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Bergman, Richard N. . . . . . . . . . . . . . . . . . .27, 28, 31, 33
Bloomgarden Zachary T. . . . . . . . . . . . . . . . . . . . . . . 26
Brethauer, Stacy A. . . . . . . . . . . . . . . . . . . . . . . . . . 28
Brown, Michael S. . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Buchwald, Henry . . . . . . . . . . . . . . . . . . . . . . 26, 28, 30
M
McGraw, Timothy E.
Mechanick, Jeffrey I.
Mingrone, Geltrude
Moore, J.J. . . . . .
C
Chowbey, Pradeep . . . . . . . . . . . . . . . . . . . . . . . 29, 30
Cohen, Ricardo V. . . . . . . . . . . . . . . . . . . . 27, 28, 30, 32
Cummings, David E. . . . . . . . . . . . . . . . . . 28, 31, 33, 34
. . . . . . . . . . . . . . . . . . . . . . . . . 33
. . . . . . . . . . . . . . . . . 26, 27, 30, 32
. . . . . . . . . . . . . . . . . . . . . . . 28, 31
. . . . . . . . . . . . . . . . . . . . . . . 29, 32
P
Pi-Sunyer, Xavier . . . . . . . . . . . . . . . . . . . . . . 26, 31, 32
Pomp, Alfons . . . . . . . . . . . . . . . . . . . . . . . . . . . 26, 30
Pories, Walter J. . . . . . . . . . . . . . . . . . 26, 27, 28, 30, 34
D
Darsow, Tamara . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Darzi, Ara . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
DeFronzo, Ralph . . . . . . . . . . . . . . . . . 27, 28, 29, 30, 33
De Paula, Aureo . . . . . . . . . . . . . . . . . . . . . . . . . 28, 30
Del Prato, Stefano . . . . . . . . . . . . . . . . . . . . . 26, 27, 31
Dixon, John . . . . . . . . . . . . . . . . . . . . . . . . . 26, 27, 30
R
Roth, Jesse . . . . . . . . . . . . . . . . . . . . . . . . . 29, 33, 34
Rubino, Francesco . . . . . . . . . . . . . . . . . . . . . 26, 29, 33
S
Saoud, Moh'd. Fathy . . . . . . . . . . . . . . . . . . . . . . . . 29
Schauer, Phillip . . . . . . . . . . . . . . . . . . . . . . . 26, 29, 30
Schwartz, Gary J. . . . . . . . . . . . . . . . . . . . . . . . . 28, 31
Seeley, Randy J. . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
Shulman, Gerald . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Sjöström, Lars V. . . . . . . . . . . . . . . . . . . . . . . . . 26, 27
Staten, Myrlene . . . . . . . . . . . . . . . . . . . . . . . . . 29, 31
Sugerman, Harvery J. . . . . . . . . . . . . . . . . . . . . . 27, 30
Sullivan, Sean D. . . . . . . . . . . . . . . . . . . . . . . . . 29, 32
E
Eckel Robert H. . . . . . . . . . . . . . . . . . . . . . . . . . 26, 27
F
Ferrannini, Ele . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 28
Flum, David R. . . . . . . . . . . . . . . . . . . . . . . . 29, 32, 34
Funder, John . . . . . . . . . . . . . . . . . . . . . . . . 28, 29, 32
G
Gagner, Michel . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 30
Galvao Neto, Manoel . . . . . . . . . . . . . . . . . . . . . . 28, 31
Goldfine Allison B. . . . . . . . . . . . . . . . . . . . . . . 26, 29, 31
Goldstein, Joseph L. . . . . . . . . . . . . . . . . . . . . . . . . . 33
Gotto, Antonio M. . . . . . . . . . . . . . . . . . . . . . . . . 26, 27
Greve, Jan Willem M. . . . . . . . . . . . . . . . . . . . . . . 28, 30
V
Van Der Merwe, Tess . . . . . . . . . . . . . . . . . . . . . . 29, 32
W
Wolfe, Bruce M. . . . . . . . . . . . . . . . . . . . . . . . . . 26, 32
Wysham, Carol H. . . . . . . . . . . . . . . . . . . . . . . . . 26, 27
Y
Young, James . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 30
H
Hill, Peter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Hofmann, Bjørn M. . . . . . . . . . . . . . . . . . . . . . . . 29, 31
Holst, Jens Juul . . . . . . . . . . . . . . . . . . . . . . . . . 28, 33
Z
Zimmet, Paul . . . . . . . . . . . . . . . . . . . . . . 26, 29, 32, 34
Zirie, Mahmoud Ali . . . . . . . . . . . . . . . . . . . . . . . . . . 29
J
Ji, Linong . . . . . . . . . . . . . . . . . . . . . . . . . . . 27, 29, 32
Joshi, Shashank R. . . . . . . . . . . . . . . . . . . . . . 27, 28, 30
K
Kahn, Steven H. . . . . . . . . . . . . . . . . . . . . .27,
. 28, 31, 33
Kaplan, Lee M. . . . . . . . . . . . . . . . . . . . . . 26, 28, 31, 33
Keating, Catherine . . . . . . . . . . . . . . . . . . . . . . . . 29, 32
Kirkman, M. Sue . . . . . . . . . . . . . . . . . . . . . . . . . 32, 34
Klein Samuel . . . . . . . . . . . . . . . . . . . . . . . . . 28, 31, 33
Korner, Judith . . . . . . . . . . . . . . . . . . . . . . 27, 28, 29, 30
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
35
Share the World Congress
with your Staff and Colleagues!
Pre-Purchase your Congress DVD today!
The information presented at the 2nd World Congress on
Interventional Therapies for Type 2 Diabetes is an invaluable
resource. The Congress DVD is the perfect way to share
all the valuable information you’ve heard here with your
colleagues and staff.
The Congress DVD will include the full session
recordings and slides from all presentations during
the Congress, including the discussions in each
of the three breakout tracks.
Purchase the DVD at the Congress Registration Desk
or after the Congress at www.wcidt.org
Cost: $165 (plus shipping)
DVD orders will be mailed in summer 2011.
TAB
Scientific Exhibits
BLANK
Back of Tab Page
EXHIBITOR DIRECTORY
American Diabetes Foundation
Ethicon Endo-Surgery
Booth 207
Booth 102
Linda Cann
+1.703.299.2068
[email protected]
Annie Havens
+1.513.337.8645
[email protected]
The American Diabetes Association is the leading non-profit
organization focused on providing resources to health care
professionals and people with diabetes to improve care and
patient outcomes. The association has a worldwide professional
membership of over 15,000 and over 425,000 lay members.
Join the new grassroots movement to “Stop Diabetes.”
Ethicon Endo-Surgery, a Johnson & Johnson company,
develops and markets advanced medical devices for minimally
invasive and open surgical procedures, focusing on procedureenabling devices for the interventional diagnosis and treatment
of conditions in general and bariatric surgery, as well as
gastrointestinal health, gynecology and surgical oncology.
More information can be found at www.ethiconendo.com.
Allergan
GI Dynamics
Booth 104
Booth 106
Pat Allen
+1.714.246.4667
[email protected]
Wade Fox
+1.781.357.3306
[email protected]
Allergan has joined the effort to fight the growing obesity
epidemic with the LAP-BAND® Adjustable Gastric Banding
System, the first minimally invasive surgical approach approved
in the United States by the FDA, to help patients achieve
sustained weight loss, realize their goals for healthy living, and
reduce obesity-related risks.
GI Dynamics is focused on developing effective, non-surgical
approaches for treating type 2 diabetes and obesity. The
company's patented EndoBarrier™ technology has the potential
to deliver medical innovations for people combating diabetes
and weight problems or diabetes risk factors. Data from clinical
trials demonstrate that the EndoBarrier may provide rapid
improvement in glycemic control and significant weight loss by
modifying metabolic pathways.
Covidien
Booth 100
Gaurav Lamba
+1.203.821.4770
[email protected]
Gore Medical Products
Booth 202
Pamela Hickey
+1.410.506.8283
[email protected]
Gina Baldo
+1.203.821.4770
[email protected]
Gore Medical Products Division has provided creative
therapeutic solutions to complex medical problems for three
decades. During that time, more than 35 million Innovative
Gore Medical Devices have been implanted, saving and
improving the quality of lives worldwide. The extensive Gore
Medical family of products includes vascular grafts, endovascular
and interventional devices, surgical materials for hernia repair,
soft tissue reconstruction, staple line reinforcement, and sutures
for use in vascular, cardiac and general surgery.
Covidien is a leading global healthcare products company that
creates innovative medical solutions for better patient outcomes
and delivers value through clinical leadership and excellence.
Covidien manufactures a diverse range of industry-leading
products in five segments including Surgical and Energy-based
Devices. Please visit www.covidien.com to learn more.
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
37
Karl Storz Endoscopy-America Inc.
Qatar Foundation and
Booth 204
Booth 203
Julia Benoit
+1.800.421.0837
[email protected]
Ramez Jaber
+9.744.454.0855
[email protected]
KARL STORZ Endoscopy-America, a leader for 65 years in
endoscopy technologies, has earned a reputation for more
than its high-quality products. The company is also well
regarded for its commitment to advancing medical technology
and research programs. Among these is dedication to the
research of Interventional Therapies for Type II Diabetes.
Qatar Foundation for Education, Science and Community
Development (QF) is supporting Qatar on its journey from
carbon economy to knowledge economy by unlocking human
potential. This will not just benefit Qatar. It will benefit the world.
QF is a private, non-profit organization founded in 1995 by His
Highness Sheikh Hamad Bin Khalifa Al-Thani, Amir of Qatar.
Its Chairperson and main driving force is Her Highness Sheikha
Moza Bint Nasser.
QF carries out its mission through three strategic pillars:
education, science and research, and community development.
QF’s education pillar brings world-class universities to Qatar to
help create an education sector in which young people can
develop the attitudes and skills required for a knowledge
economy. Meanwhile, its science and research pillar builds
Qatar's innovation and technology capacity by developing
and commercializing solutions through key sciences. Finally,
its community development pillar helps foster a progressive
society while also enhancing cultural life, protecting Qatar’s
heritage and addressing immediate social needs in the
community.
For a complete list of QF’s initiatives and projects, visit
http://www.qf.org.qa
Rhinelander Gallery - Exhibits and Posters
WIFI
HOTSPOT
AREA
206
204 202
200
207
205 203
106
104 102
ENTRANCE
38
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
201
100
TAB
Posters
BLANK
Back of Tab Page
Please refer to the Abstract Book for
POSTER SESSIONS
Rhinelander Gallery
Poster Display and Viewing:
Monday, March 28: 7:00 am - 6:45 pm
Tuesday, March 29: 6:30 am - 3:00 pm
Poster Sessions:
One of the authors is required to attend his or her poster as follows.
The formal poster session will be on Monday March 28 from 5:45 pm-6:45 pm.
The Presenting Author is highlighted in bold
Please refer to the Abstract Book for the complete listing of Poster Sessions and Abstracts
An Author Index is included immediately following the Abstracts Listing.
*Special Note: Posters marked with YIA are competing for the Young Investigator Award.
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
39
40
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
TAB
Additional Resources
BLANK
Back of Tab Page
Diabetes: A Global Epidemic
■
Diabetes currently affects 285 million people worldwide
and is expected to affect 438 million by 2030.
■
In 2010, the five countries with the largest numbers of
people with diabetes were India (50.8 million), China
(43.2 million), the United States (26.8 million), Russia
(9.6 million), and Brazil (7.6 million).
■
In 2010, the five countries with the highest diabetes
prevalence in the adult population were Nauru (30.9%),
United Arab Emirates (18.7%), Saudi Arabia (16.8%),
Mauritius (16.2%), and Bahrain (15.4%).
■
By 2030, the largest increases in diabetes prevalence will
take place in developing countries.
■
Each year a further 7.7 million people develop diabetes.
■
Each year 4 million deaths are attributable to diabetes.
An even greater number die from cardiovascular disease
made worse by diabetes-related lipid disorders and
hypertension.
■
Every 10 seconds a person dies from diabetes-related
causes.
■
Every 10 seconds two people develop diabetes.
■
Diabetes is the fourth leading cause of global death by
disease.
■
At least 50% of all people with diabetes are unaware of
their condition. In some countries this figure may reach
80%.
■
At least 60% of new cases of type 2 diabetes is
preventable by adopting a healthy diet and increasing
physical activity.
■
Diabetes is the largest cause of kidney failure in developed
countries and is responsible for huge dialysis costs.
■
Type 2 diabetes has become the most frequent
condition in people with kidney failure in countries of the
Western world. The reported incidence varies
between 30% and 40% in countries such as Germany
and the USA.
■
10% to 20% of people with diabetes die of renal failure.
■
It is estimated that more than 2.5 million people
worldwide are affected by diabetic retinopathy.
■
Diabetic retinopathy is the leading cause of vision
loss in adults of working age (20 to 65 years) in
industrialized countries.
■
On average, people with type 2 diabetes will die 5-10
years before people without diabetes, mostly due to
cardiovascular disease.
■
Cardiovascular disease is the major cause of death in
diabetes, accounting for some 50% of all diabetes
fatalities, and much disability.
■
People with type 2 diabetes are over twice as likely to
have a heart attack or stroke as people who do not have
diabetes. Indeed, people with type 2 diabetes are as likely
to suffer a heart attack as people without diabetes who
have already had a heart attack.
Sources:
Diabetes Atlas, fourth edition,
International Diabetes Federation, 2009.
Diabetes Fact Sheets:
Time to Act, International Diabetes Federation, 2004.
World Health Organisation Diabetes Unit - www.who.int/diabetes.
Diabetes currently affects 285 million people worldwide,
according to the International Diabetes Federation (IDF).
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
41
Conventional Bariatric/Metabolic Procedures
Roux-en-Y Gastric Bypass (RYGB)
After its first report by Edward Mason in 1967, the
technique of gastric bypass has undergone several
modifications. The current technique involves the use of
a surgical stapler to create a small and vertically oriented
gastric pouch usually less than 30 cc in size. The upper
pouch, which is completely divided from the gastric
remnant is anastomosed to the jejunum (between 30 and
75 cm from the ligament of Treitz). Bowel continuity is
restored by an entero-entero anastomosis between the
excluded biliary limb and the alimentary limb usually
75-to 100 cm distal to the gastro-jejunostomy. After
RYGB, ingested food bypasses approximately 95% of
the stomach, the entire duodenum and a portion of the
jejunum, but bile and nutrients mix in the distal jejunum
and can be absorbed through the remaining portion of
the small bowel (jejunum-ileum).
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
43
Laparoscopic Adjustable Gastric Banding (LAGB)
The LAGB is a restrictive procedure that involves encircling
the upper part of the stomach with a band-like, saline-filled
tube just distal to the gastroesophageal junction. The
amount of restriction may be adjusted by injecting or
withdrawing saline solution from the hollow core of the
band through a subcutaneous port.
Sleeve Gastrectomy (SG)
Sleeve gastrectomy is a component of BPD-DS; an operation that can be performed in two stages (sleeve gastrectomy first, followed by the intestinal rearrangement months
later) to reduce operative time and minimize surgical risk in
super-obese patients (BMI>60). The dramatic weight loss
consequent to the first stage of the BPD-DS has
encouraged the use of SG as a stand-alone procedure.
In addition to reducing the capacity of the stomach, SG
eliminates the ghrelin-rich gastric fundus and can cause
changes in intra-gastric pressure and gastric motility, all
of which might play a role in the mechanism of action of
the operation. Sleeve gastrectomy has been also shown to
substantially improve diabetes in severely obese patients
as well as in experimental rodent models of diabetes. The
long-term (>5 years) clinical efficacy of the procedure is still
under investigation.
44
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
Biliopancreatic Diversion (BPD) and BPD-DS
Figure 1A
The operation involves a gastric resection (usually leaving
behind a 200-500 ml sized stomach) + a long intestinal
bypass. The gastric resection can be horizontal as in the
Scopinaro procedure (Fig 1A) or vertical - “sleeve
gastrectomy” in its variant named “BPD-Duodenal
Switch”- Fig 1B). The remnant stomach is anastomosed
to the distal 250 cm of small intestine (called alimentary
limb). The excluded small intestine (including the
duodenum, the jejunum and part of the proximal ileum)
carries the bile and pancreatic secretions (biliary limb) and
is connected to the alimentary channel just 50-100 cm
proximal to the ileocecal valve. The short segment of small
bowel where bile and nutrients mix is called “common
limb” and is the only site where fat and starches are
absorbed, whereas the alimentary limb (usually 200-250
cm in length) allows only partial absorption of nutrients.
Figure 1B
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
45
Investigational Gastrointestinal Procedures
Duodenal-Jejunal Bypass (DJB)
Figure 2A
Originally described by Rubino as an experimental
procedure to investigate mechanisms of action of gastric
bypass surgery, the operation consists of a stomachpreserving bypass of a short segment of proximal small
intestine, equivalent to the amount of intestine bypassed
in a standard gastric bypass (RYGB). A variant of this
procedure includes the association of proximal intestinal
bypass with sleeve resection of the stomach (DJB-SGFig 2B) to reduce potential for marginal ulcerations and
potentially increase clinical efficacy. These procedures
have been used to treat diabetes in low BMI patients
(R. Cohen and others). Long-term efficacy data are not
yet available and these procedures should be considered
investigational in humans.
Figure 2B
46
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
Investigational Gastrointestinal Procedures
Ileal Interposition (IT)
The concept of ileal-interposition was first described by
Koopmans and Sclafani in rodents experiments as a
weight loss procedure. A small segment of ileum with its
vascular and nervous supplies intact, is surgically interposed
into the proximal small intestine, accelerating its exposure
to ingested nutrients. IT can be performed alone or in
association with sleeve gastrectomy and duodenal exclusion.
The procedure requires a minimum of 3 anastomosis
(vs the 2 of gastric bypass operations) and is technically
complex, especially when associated with sleeve
gastrectomy or duodenal exclusion. Early human studies
suggest that these procedures can improve diabetes in
non-obese subjects; however, long-term metabolic
sequalae are unknown, and long-term safety is still to be
evaluated. The procedure should be considered
experimental in humans.
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
47
Disclosures
Faculty Disclosures
Apovian, Caroline M.
Consultant: Amylin, Orexigen, Allergan, Pfizer, Johnson &
Johnson, Abott, Merck, GI Dynamics
Grant/Research: Atkins Foundation, MetaProteomics, Amylin,
Orexigen
Dixon, John B.
Consultant: Allergan Inc., Metagenics (Bariatric Advantage),
Scientific Intake
Speaker’s Bureau: Metagencis (Bariatirc Advantage), Eli Lilly,
Nestle Australia, Optifast Medical Advisory Board
Grant/Research (Principal): Allergan Inc., Nestle Australia, Optifast Medical Advisory Board, ResMed, Scientific Intake
Course Director: Florida Hospital
Course Co-Director: MISS
Aronne, Louis J.
Contracted Research: Amylin Pharmaceuticals, Inc.,
F. Hoffmann-La Roche Ltd., Novo Nordisk, Orexigen
Therapeutics, Inc.
Consultant/Advisory Boards: Abbott Laboratories, Amylin
Pharmaceuticals, Inc., GI Dynamics, Inc., Roche Laboratories,
Inc., Johnson & Johnson, NeuroSearch, Inc., Novo Nordisk,
Orexigen Therapeutics, Inc., VIVUS, Inc., GlaxoSmithKline
Consumer Healthcare, LP
Ownership Interest: Cardiometabolic Support Network, LLC
Funder, John
Consultant: Pfizer, Merck, CBio, Allergan, Novo NorDisk
Gagner, Michel
Speaker’s Bureau: Ethicon, Olympus, CineMed, Coviden
Grant/Research Support (Principal): GORE
Galvao Neto, Manoel
Consultant: Ethicon Endo Surgery, GI Dynamics
Bergman, Richard N.
Consultant: Tethys
Grant/Research Support (Principal): Amylin
Greve, Jan Willem M.
Consultant: GI Dynamics
Grant/Research Support (Principal): GI Dynamics
Bloomgarden, Zachary T.
Consultant: BMS/AZ, Merck, Novo Nordisk
Speaker’s Bureau: Merck, Novo Nordisk, GlaxoSmithKlien,
BMS BI
Stock Shareholder (self managed): Bard, CVS, Roche, Novartis,
St. Jude
Kahn, Steven H.
Consultant: Boenringer Ingelheim, Eli Lilly, GlaxoSmithKlien,
Intarcia Therapeutics, Merck, Novo Nordisk
Grant/Research: Daiichi Sankyo
Brethauer, Stacy A.
Consultant: Ethicon Endo
Speaker’s Bureau: Ethicon Endo, Covidien
Grant/Research Support (Principal): Bard/Davol, Ethicon Endo
Kaplan, Lee
Consultant: GI Dynamics
Grant/Research (Principal): GI Dynamics
Keating, Catherine
Grant/Research Support (Principal): Allergan Health
Buchwald, Henry
Consultant: Ethicon Endo-Surgery, Fulfillium, Metacure
Grant/Reserach Support (Principal): Meacure, Ethicon
Endo-Surgery, WE Gore
Stock Shareholder (self managed): Metacure
Klein, Samuel
Consultant: Amylin, Dannon/Yakult, Ethicon Endosurgery,
Merck, Orexigen, Takeda Pharmaceuticals, Vivus
Pharmaceuticals
Speaker’s Bureau: Merck
Grant/Research Support (Principal): National Institute of Health
(NIH), Barnes-Jewish Hospital Foundation, DSM Nutritional
Products, Endo-Ethicon Surgery, Pfizer
Stockholder: Aspirations Medical Technologies
Endowments: Atkins Foundation Charitable Trust, Kilo
Foundation
Cummings, David E.
Grant/Research (Principal): Johnson & Johnson, Ethicon
Endosurgery
Darsow, Tamara
Stock Shareholder (self managed): Amylin
Darzi, Ara
Consultant: Covidien
Korner, Judith
Grant/Research Support (Principal): Covidien
Scientific Advisory Board: Nutrisystem
DeFronzo, Ralph
Consultant: Takeda, Amylin, ISIS, Boehringer Ingelheim
Speaker’s Bureau: Novo Nordisk
Grant/Reserach Support (Principle): Takeda, Amylin
Lautz, David
Grant/Research (Principal): Covidien
Del Prato, Stefano
Speaker’s Bureau: GlaxoSmithKline, Sanofi-Aventis
Grant/Research Support (Principle): Merck & Co., Sanofi-Aventis,
Novo Nordisk
Advisory Panels: Novartis Pharmaceuticals, Merck & Co.,
Roche Pharmaceuticals, Roche Diagnostics Corporation, Pfizer
Inc., Eli Lilly & Co., Amylin Pharmaceuticals, Inc., Mannkind
Corporation; Boehringer Ingelheim, Bristol-Meyers Squibb,
Novo Nordisk
48
Lebovitz, Harold E.
Consultant: Amylin Corporation, Astra-Zeneca, Biocon Pharma,
Enzymotec, Glaxo Smith Kline (International), MetaCure,
Sanofi-Aventis
Speaker’s Bureau: Glaxo Smith Kline (International)
Stockholder: Merck
Advisory Board: Amylin Corporation, ATTCC, Biocon Pharma,
Indigene, Intra Pharmaceuticals, Merck, MetaCure, Poxel Pharma
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
Disclosures
Faculty Disclosures
Faculty With No Conflicts of Interest
Pi-Sunyer, Xavier
Consultant: Amylin, McNeil Nutritionals, Novo Nordiak, Vivus
Inc., Weight Watchers, Orezigen
Accili, Domenico
Adams, Ted D.
Alberti, Sir K. George
Amiel, Stephanie A.
Basso, Nicola
Brown, Michael S.
Chowbey, Pradeep
Cohen, Ricardo V.
De Paula, Aureo Ludovico
Eckel, Robert H.
Ferrannini, Ele
Flum, David R.
Goldfine, Allison B.
Goldstein, Joseph L.
Gotto, Jr., Antonio M.
Hill, Peter
Hofmann, Bjorn
Holst, Jens Juul Holst
Ji, Linong
Joshi, Shashank R.
Kirkman, Sue
Laferrere, Blandine B.
Lakdawala, Muffazal Abdulkader
Le Roux, Carel W.
Lefevre, Frank
Leibel, Rudolph L.
Ley, Ruth
Li, Rui
McGraw, Timothy E.
Mechanick, Jeffrey I.
Mingrone, Geltrude
Moore, John J.
Pomp, Alfons
Roth, Jesse
Saoud, Mohammed Fathy
Schwartz, Gary
Shulman, Gerald
Staten, Myrlene
Sugerman, Harvey J.
Sullivan, Sean D.
Van Der Merwe, Tess
Wolfe, Bruce
Young, James
Zimmet, Paul
Zirie, Mahmoud Ali
Pories, Walter J.
Consultant: Johnson & Johnson
Grant/Research (Principal): Johnson & Johnson, GlaxoSmithKline
Rubino, Francesco
Consultant: NGM Biotech
Grant/Research Support (Principal): Covidien, Roche
Schauer, Phillip
Consultant: Gore
Grant/Research (Principal): Baxter, Covidien, Allergan
Board of Directors: Remedy MD, Surgical Excellence LLC
Scientific Advisory Board: Ethicon Endosurgery, Stryker
Endoscopy, Bard-Davol, Barosense, Surgiquest,
Cardinal/Snowden Pencer
Seeley, Randy J.
Consultant: Ethicon Endo
Speaker’s Bureau: Novo Nordisk
Grant/Research Support (Principal): Ethicon Endo, Novo
Nordisk
Sjöström, Lars V.
Consultant: AZ, Johnson & Johnson, Several
Grant/Research Support (Principle): Johnson & Johnson,
Roche, Sanofi
Wysham, Carol H.
Consultant: Amylin Pharmaceuticals
Speaker’s Bureau: Sanofi Aventis, Amylin Pharma
•
March 28-30, 2011
•
New York, NY, USA
•
www.wcidt.org
49
Visionary Level Supporter
Corporate Sponsors
Platinum Level
Gold Level
Silver Level
Bronze Level
We would also like to thank
G.R.I.N. FOUNDATION
50
www.wcidt.org
Giovanni Lorenzini Medical Foundation
6535 Fannin, MS A-601
Suite A754
Houston, TX 77030
Tel: +1 713 797 0401 • Fax: +1 713 796 8853

2nd World Congress on Interventional Therapies for Type 2 Diabetes

Transcription

Similar documents

Education

ARC factsheet Special Research Initiative for Type 1 Juvenile

Hear Ye. Hear Ye - Diabetic Society of Singapore

Tim McGraw has a challenge for you.

NIDDK Medical Student Research Program in Diabetes and Obesity

TONY SONG, CEO DIABETES CARE PARTNERS tony

Originally Published in the News

Living with diabetes